Evidence map›Paper›PMID 30612555›Full record

ArticleBMC cancer2019

miR-632 promotes gastric cancer progression by accelerating angiogenesis in a TFF1-dependent manner.

Ying Shi, Xiaoxiao Huang, Guobin Chen, Ying Wang, Yuansheng Liu, Wei Xu, Shaohui Tang, Bayasi Guleng, Jingjing Liu, Jianlin Ren

Abstract read
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Pathogens (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Article
  7. Regulation of angiogenesis by microRNAs in cancer.Molecular medicine reports · 2021
    Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying ShiDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, 510630, People's Republic of China. shiying@jnu.edu.cn.ORCID http://orcid.org/0000-0002-1764-7658
Xiaoxiao HuangDepartment of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, People's Republic of China.
Guobin ChenXiamen branch, Zhongshan hospital, Fudan University, Xiamen, 361015, People's Republic of China.
Ying WangXiamen branch, Zhongshan hospital, Fudan University, Xiamen, 361015, People's Republic of China.
Yuansheng LiuDepartment of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, People's Republic of China.
Wei XuDepartment of Gastroenterology, The Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, People's Republic of China.
Shaohui TangDepartment of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, 510630, People's Republic of China.
Bayasi GulengDepartment of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, People's Republic of China.
Jingjing LiuDepartment of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, People's Republic of China. jingjingliu@xmu.edu.cn.
Jianlin RenDepartment of Gastroenterology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, People's Republic of China. renjianl@xmu.edu.cn.

Funding

Medical Research Fund of Guangdong Province, China A2018011Ministry of Health Foundation for State Key Clinical Department, 863 and 973 programs 2015CB553800National Natural Science Foundation of China 81370505National Natural Science Foundation of China 81370591Natural Science Foundation of Guangdong Province (CN) 2018A0303130302Research Foundation for Talented Scholars of Jinan University (CN) 89018021Science Foundation for The Excellent Youth Scholars of Jinan University, China 21618302Xiamen Union Research Project of Major Disease 3502z20149031
6 · The paper itself

Abstract

backgroundGastric cancer (GC) is a common malignant disease worldwide. Aberrant miRNAs expression contributes to malignant cells behaviour, and in preclinical research, miRNA targeting has shown potential for improving GC therapy. Our present study demonstrated that miR-632 promotes GC progression in a trefoil factor 1 (TFF1)-dependent manner.

methodsWe collected GC tissues and serum samples to detect miR-632 expression using real-time PCR. A dual-luciferase reporter assay was used to identify whether miR-632 directly regulates TFF1 expression. Tube formation and endothelial cell recruitment assays were performed with or without miR-632 treatment. Western blot and in situ hybridization assays were performed to detect angiogenesis and endothelial recruitment markers that are affected by miR-632.

resultsOur results showed that miR-632 is highly expressed in GC tissue and serum and negatively associated with TFF1 in GC. miR-632 improves tube formation and endothelial cell recruitment by negatively regulating TFF1 in GC cells. Recombinant TFF1 reversed miR-632-mediated angiogenesis. TFF1 is a target gene of miR-632.

conclusionsOur study demonstrated that miR-632 promotes GC progression by accelerating angiogenesis in a TFF1-dependent manner. Targeting of miR-632 may be a potential therapeutic approach for GC patients.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansIn Situ HybridizationMaleMicroRNAsMiddle AgedNeovascularization, PathologicStomachStomach NeoplasmsTrefoil Factor-1MicroRNAsMIRN632 microRNA, humanTFF1 protein, humanTrefoil Factor-1AngiogenesisGastric cancermiR-632Trefoil factor 1

Identifiers

PMID30612555
PMCPMC6322242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.